EGFR and non-small cell lung carcinoma: Dacomitinib, a second-generation EGFR-TKI, has been approved for the treatment of advanced NSCLC harboring EGFR exon 19 (19 del) and Leu858Arg point mutation (L858R) in exon 21 mutation.